follitropin alfa + lutropin alfa: prescribing and clinical use
Focused clinical detail for use alongside current product information, local policy and patient-specific assessment.
follitropin alfa + lutropin alfa: clinical details
Prescribing considerations
- Initiate and supervise treatment within a fertility service experienced in gonadotrophin therapy.
- Assess the cause of infertility and contraindications to pregnancy before treatment; investigate and manage thyroid dysfunction, adrenal insufficiency and hyperprolactinaemia where relevant.
- Consider baseline risks for ovarian hyperstimulation, multiple pregnancy, ectopic pregnancy, ovarian torsion and thromboembolism.
- Record the product name and batch number for biological-medicine traceability.
- Renal and hepatic impairment have not been adequately studied.
- Closely monitor patients with porphyria or a family history of porphyria.
Contraindications and cautions
- Hypersensitivity to either active ingredient or an excipient
- Hypothalamic or pituitary tumour
- Unexplained ovarian enlargement or ovarian cyst not related to polycystic ovarian disease
- Unexplained gynaecological bleeding
- Ovarian, uterine or breast carcinoma
- Primary ovarian failure
- Reproductive-organ malformation or uterine fibroid incompatible with pregnancy
Monitoring
- Follicular development by ultrasound
- Serum oestradiol alongside ultrasound where appropriate
- Clinical and biochemical evidence of excessive ovarian response or ovarian hyperstimulation syndrome
- Symptoms of ovarian torsion, ectopic pregnancy or thromboembolism
- Porphyria symptoms in susceptible patients
Clinical pharmacology
This combination contains recombinant human FSH and LH. FSH promotes granulosa-cell activity and follicular growth; LH stimulates theca-cell androgen production and supports oestradiol synthesis, steroidogenesis and follicular maturation. The liquid and freeze-dried formulations are bioequivalent, and simultaneous administration does not produce a pharmacokinetic interaction between the components.
Formulation and product differences
- The pre-filled pen contains a ready-to-use multidose solution and must not be mixed with another medicine in the same injection.
- The vial is a single-use powder supplied with solvent. It must be gently reconstituted immediately before injection and may be mixed with licensed follitropin alfa where prescribed.
- The pen solution is refrigerated before use and protected from light. The powder-and-solvent product is stored below its specified room-temperature limit and protected from light.
follitropin alfa + lutropin alfa preparations and strengths
Injection
Route: Parenteral
Strengths: 150 units + 75 units
follitropin alfa + lutropin alfa interactions
No pharmacokinetic interaction occurs between the two active ingredients, but injection compatibility differs between formulations.
Other injectable medicines
Do not combine them with the pre-filled pen solution in the same injection.
Licensed follitropin alfa preparations
When prescribed alongside the pen, administer as a separate injection. The powder formulation may be mixed with follitropin alfa as described in its product instructions.
Sources
These sources were used to prepare and review this medicine page.
Prepared and reviewed by the iatroX editorial team.